CLARITY-AD (lecanemab) · 2023 · New England Journal of Medicine
Lecanemab in Early Alzheimer’s Disease
Lecanemab slows cognitive decline in early Alzheimer disease with amyloid confirmation, with a non-trivial ARIA safety signal.
Source publication
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck et al. · New England Journal of Medicine · 2023
Sponsor
Eisai Inc.
Principal investigator
—
Population
Early Alzheimer's Disease; n=1906
Primary endpoint
Core Study: Change from Baseline in the CDR-SB at 18 Months
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$2.0M / $3.5M
56%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1